Passivity-Based Inverse Optimal Impulsive Control for Influenza Treatment in the Host

Influenza A virus infections are causes of severe illness resulting in high levels of mortality. Neuraminidase inhibitors such as zanamivir and oseltamivir are used to treat influenza; however, treatment recommendations remain debatable. In this paper, a discrete-time inverse optimal impulsive control scheme based on passivation is proposed to address the antiviral treatment scheduling problem. We adapt results regarding stability, passivity, and optimality for the impulsive action. The study is founded on mathematical models whose parameters are adjusted to data from clinical trials where participants were experimentally infected with influenza H1N1 and treated with either zanamivir or oseltamivir. Simulation results show that control-based techniques can reduce the amount of medication while simultaneously reach the efficacy levels of the treatment schedules by the Food and Drug Administration. Monte Carlo simulations disclose the robustness of the proposed control-based techniques.

[1]  F. Hayden,et al.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.

[2]  N. J. White,et al.  Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[3]  Florian Krammer,et al.  Influenza virus hemagglutinin stalk-based antibodies and vaccines. , 2013, Current opinion in virology.

[4]  V. Georgiev,et al.  National Institute of Allergy and Infectious Diseases, NI , 2008 .

[5]  Isaac I. Bogoch,et al.  Have you herd? Indirect flu vaccine effects are critically important. , 2017, The Lancet. Public health.

[6]  Ryan Zurakowski,et al.  Nonlinear observer output-feedback MPC treatment scheduling for HIV , 2011, Biomedical engineering online.

[7]  Alma Y. Alanis,et al.  Inverse Optimal Impulsive Control Based Treatment of Influenza Infection , 2017 .

[8]  L. Jakubcová,et al.  Comparison of infectious influenza A virus quantification methods employing immuno-staining. , 2017, Journal of virological methods.

[9]  Donald E. Kirk,et al.  Optimal control theory : an introduction , 1970 .

[10]  Van Kinh Nguyen,et al.  Windows of opportunity for Ebola virus infection treatment and vaccination , 2017, bioRxiv.

[11]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[12]  Alma Y. Alanis,et al.  Recurrent High Order Neural Networks Identification for Infectious Diseases , 2018, 2018 International Joint Conference on Neural Networks (IJCNN).

[13]  Satoshi Fukuyama,et al.  The pathogenesis of influenza virus infections: the contributions of virus and host factors. , 2011, Current opinion in immunology.

[14]  D. Normand-Cyrot,et al.  Control Lyapunov stabilization of affine discrete-time systems , 1997, Proceedings of the 36th IEEE Conference on Decision and Control.

[15]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[16]  Alma Y. Alanis,et al.  Impulsive MPC for Influenza Infection Treatment at Variable Time , 2018 .

[17]  E. D. Kilbourne Influenza Pandemics of the 20th Century , 2006, Emerging infectious diseases.

[18]  C. Abdallah,et al.  Optimal discrete-time control for non-linear cascade systems , 1998 .

[19]  Katherine L. Milkman,et al.  Using implementation intentions prompts to enhance influenza vaccination rates , 2011, Proceedings of the National Academy of Sciences.

[20]  E. Sánchez,et al.  Inverse optimal control for discrete‐time nonlinear systems via passivation , 2014 .

[21]  B. Davies,et al.  Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations , 2010, The Journal of antimicrobial chemotherapy.

[22]  Andreas Handel,et al.  Neuraminidase Inhibitor Resistance in Influenza: Assessing the Danger of Its Generation and Spread , 2007, PLoS Comput. Biol..

[23]  Alma Y. Alanis,et al.  Neural inverse optimal control for discrete-time impulsive systems , 2018, Neurocomputing.

[24]  Xiaohua Xia,et al.  Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review , 2014, BioResearch open access.

[25]  Vlado Dančík,et al.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza. , 2016, Trends in microbiology.

[26]  Ronald Gieschke,et al.  Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid , 2008, Journal of clinical pharmacology.

[27]  Tao Yang,et al.  Impulsive control , 1999, IEEE Trans. Autom. Control..

[28]  Yu-Ann Fang,et al.  Influenza Vaccination is Associated with Lower Risk of Acute Coronary Syndrome in Elderly Patients with Chronic Kidney Disease , 2016, Medicine.

[29]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[30]  Andreas Handel,et al.  Towards a quantitative understanding of the within-host dynamics of influenza A infections , 2010, Journal of The Royal Society Interface.

[31]  Jennifer L. Reed,et al.  Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses , 2007, The Journal of infectious diseases.

[32]  S. Hensley,et al.  Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. , 2014, Current opinion in virology.

[33]  Alan S. Perelson,et al.  Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus , 2010, Journal of Virology.

[34]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[35]  Takeshi Kurata,et al.  Defense mechanisms against influenza virus infection in the respiratory tract mucosa. , 2004, Japanese journal of infectious diseases.

[36]  A. Perelson,et al.  Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.

[37]  R.A. Freeman,et al.  Optimal nonlinear controllers for feedback linearizable systems , 1995, Proceedings of 1995 American Control Conference - ACC'95.

[38]  Esteban A. Hernandez-Vargas,et al.  Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection , 2016, Front. Cell. Infect. Microbiol..

[39]  Isaac Chairez Oria,et al.  Nonlinear discrete time neural network observer , 2013, Neurocomputing.

[40]  B. Anderson,et al.  Optimal control: linear quadratic methods , 1990 .

[41]  Nicholas J. White,et al.  Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 Influenza , 2008, PloS one.

[42]  Michael Meyer-Hermann,et al.  PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections. , 2018, Progress in biophysics and molecular biology.

[43]  Alan S. Perelson,et al.  Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study , 2014, PLoS Comput. Biol..

[44]  Michael Meyer-Hermann,et al.  Modeling Influenza Virus Infection: A Roadmap for Influenza Research , 2015, Viruses.

[45]  Richard H. Middleton,et al.  Computer simulation of structured treatment interruption for HIV infection , 2011, Comput. Methods Programs Biomed..

[46]  L. Fabrigar,et al.  Using behavior change frameworks to improve healthcare worker influenza vaccination rates: A systematic review. , 2016, Vaccine.

[47]  Pyung Hun Chang,et al.  Time Delay Observer: A Robust Observer for Nonlinear Plants , 1997 .

[48]  Alma Y. Alanis,et al.  Observers for biological systems , 2014, Appl. Soft Comput..

[49]  Nathorn Chaiyakunapruk,et al.  Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics , 2017, British journal of clinical pharmacology.

[50]  John Samuel,et al.  A simple cellular automaton model for influenza A viral infections. , 2004, Journal of theoretical biology.